Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Migraine

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    October 2021
  1. MACGREGOR EA
    Differences Between Perimenstrual Migraine Attacks and Migraine Attacks at Other Times of the Cycle.
    Neurology. 2021;97:e1753-e1756.
    PubMed    


  2. RIANT F, Roos C, Roubertie A, Barbance C, et al
    Hemiplegic Migraine Associated With PRRT2 Mutations: A Clinical and Genetic Study.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012947.
    PubMed     Abstract available


  3. GUO Y, Daghlas I, Gormley P, Giulianini F, et al
    Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subtractions.
    Neurology. 2021 Oct 11. pii: WNL.0000000000012919.
    PubMed     Abstract available


    September 2021
  4. STANYER EC, Creeney H, Nesbitt AD, Robert Holland PR, et al
    Subjective Sleep Quality and Sleep Architecture in Patients With Migraine: A Meta-analysis.
    Neurology. 2021 Sep 22. pii: WNL.0000000000012701.
    PubMed     Abstract available


  5. KAISER EA, McAdams H, Igdalova A, Haggerty EB, et al
    Reflexive Eye Closure in Response to Cone and Melanopsin Stimulation: A Study of Implicit Measures of Light Sensitivity in Migraine.
    Neurology. 2021 Sep 7. pii: WNL.0000000000012734.
    PubMed     Abstract available


  6. VAN CASTEREN DS, Verhagen IE, van der Arend BWH, van Zwet EW, et al
    Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary.
    Neurology. 2021 Sep 7. pii: WNL.0000000000012723.
    PubMed     Abstract available


    August 2021
  7. SCHANKIN CJ, Denier N, El-Koussy M, Wiest R, et al
    Author Response: The Index Vein Pointing to the Origin of the Migraine Aura Symptom: A Case Series.
    Neurology. 2021;97:402.
    PubMed    


  8. BUGNICOURT JM, Godefroy O
    Reader Response: The Index Vein Pointing to the Origin of the Migraine Aura Symptom: A Case Series.
    Neurology. 2021;97:401-402.
    PubMed    


    July 2021
  9. CARVALHO G, Mehnert J, Basedau H, Luedtke K, et al
    Brain Processing of a Visual Self-Motion Study in Patients With Migraine: An fMRI Study.
    Neurology. 2021 Jul 21. pii: WNL.0000000000012443.
    PubMed     Abstract available


    April 2021
  10. MACDONALD CJ, El Fatouhi D, Madika AL, Fagherazzi G, et al
    Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000011986.
    PubMed     Abstract available


  11. GHANIZADA H, Al-Mahdi Al-Karagholi M, Arngrim N, Morch-Rasmussen M, et al
    Effect of Adrenomedullin on Migraine-like Attacks in Patients With Migraine: A Randomized Crossover Study.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011930.
    PubMed     Abstract available


  12. LIPTON RB, Buse DC, Friedman BW
    Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:686.
    PubMed    


  13. MINEN MT
    Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:685.
    PubMed    


  14. LIPTON RB, Buse DC, Friedman BW
    Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:684-685.
    PubMed    


  15. BLUMENFELD A
    Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:684.
    PubMed    


  16. LIPTON RB, Buse DC, Friedman BW
    Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:683-684.
    PubMed    


  17. GUPTA VK
    Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:683.
    PubMed    


  18. GANESH A, Galetta S
    Editors' Note: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study.
    Neurology. 2021;96:682.
    PubMed    


  19. GUO Y, Rist PM, Sabater Lleal M, de Vries P, et al
    Association Between Hemostatic Profile and Migraine: A Mendelian Randomization Analysis.
    Neurology. 2021 Apr 1. pii: WNL.0000000000011931.
    PubMed     Abstract available


    February 2021
  20. YU AYX, Hill MD, Asdaghi N, Boulanger JM, et al
    Sex Differences in Diagnosis and Diagnostic Revision of Suspected Minor Cerebral Ischemic Events.
    Neurology. 2021;96:e732-e739.
    PubMed     Abstract available


    January 2021
  21. VAN CASTEREN DS, Kurth T, Danser AHJ, Terwindt GM, et al
    Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:162-170.
    PubMed     Abstract available


    November 2020
  22. RIGGINS NY, Sawhney H, Ehrlich A, Parekh M, et al
    Inpatient infusion treatments of headache in patients with chronic migraine and a reported history of head trauma and endocrine co-morbidities.
    Neurology. 2020;95.
    PubMed     Abstract available


  23. ROBBINS MS, Victorio MC, Bailey M, Cook C, et al
    Quality improvement in neurology: Headache Quality Measurement Set.
    Neurology. 2020;95:866-873.
    PubMed    


    October 2020
  24. LIPTON RB, Fanning KM, Buse DC, Martin VT, et al
    Author response: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.
    Neurology. 2020;95:707-708.
    PubMed    


  25. GUPTA VK
    Reader response: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.
    Neurology. 2020;95:707.
    PubMed    


  26. SIEGLER JE 3RD, Galetta S
    Editors' note: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.
    Neurology. 2020;95:706.
    PubMed    


  27. SASIKUMAR S, Micieli JA, Oh J
    Mystery Case: Migraine, hearing loss, and blurred vision in a young woman.
    Neurology. 2020 Oct 12. pii: WNL.0000000000011034.
    PubMed    


    September 2020
  28. ZIEGELER C, Mehnert J, Asmussen K, May A, et al
    Central effects of erenumab in migraine patients: An event-related functional imaging study.
    Neurology. 2020 Sep 11. pii: WNL.0000000000010740.
    PubMed     Abstract available


  29. GOADSBY PJ, Silberstein SD, Yeung PP, Cohen JM, et al
    LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY.
    Neurology. 2020 Sep 10. pii: WNL.0000000000010600.
    PubMed     Abstract available


  30. KORNBLUH AB, Chung MG
    Teaching NeuroImages: Transient cytotoxic edema in a child with a novel ATP1A2 mutation.
    Neurology. 2020;95:e1441-e1442.
    PubMed    


    August 2020
  31. SALTER A, Kowalec K, Fitzgerald KC, Cutter G, et al
    Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
    Neurology. 2020;95:e446-e456.
    PubMed     Abstract available


  32. LIPTON RB, Cohen JM, Gandhi SK, Yang R, et al
    Effect of Fremanezumab on Quality of Life and Productivity in Patients With Chronic Migraine.
    Neurology. 2020 Aug 3. pii: WNL.0000000000010000.
    PubMed     Abstract available


    July 2020
  33. THALER AI, Kim BD, Fara MG
    Teaching NeuroImages: MR Perfusion and Diffusion Findings in Hemiplegic Migraine.
    Neurology. 2020 Jul 9. pii: WNL.0000000000010249.
    PubMed    


  34. GOADSBY PJ, Reuter U, Hallstrom Y, Broessner G, et al
    One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
    Neurology. 2020 Jul 7. pii: WNL.0000000000010019.
    PubMed     Abstract available


    June 2020
  35. LIPTON RB, Buse DC, Friedman BW, Feder L, et al
    Characterizing opioid use in a US population with migraine: Results from the CaMEO study.
    Neurology. 2020 Jun 11. pii: WNL.0000000000009324.
    PubMed     Abstract available


    May 2020

  36. Vascular safety of erenumab for migraine prevention.
    Neurology. 2020 May 7. pii: WNL.0000000000009310.
    PubMed    


  37. KUMAR A, Bhatia R, Sharma G, Dhanlika D, et al
    Effect of yoga as add-on therapy in migraine (CONTAIN): A randomized clinical trial.
    Neurology. 2020 May 6. pii: WNL.0000000000009473.
    PubMed     Abstract available


    April 2020
  38. SLAVOVA N, Denier N, El-Koussy M, Wiest R, et al
    The index vein pointing to the origin of the migraine aura symptom: A case series.
    Neurology. 2020 Apr 23. pii: WNL.0000000000009493.
    PubMed     Abstract available



  39. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Neurology. 2020 Apr 23. pii: WNL.0000000000009280.
    PubMed    


    March 2020
  40. LIPTON RB, Goadsby PJ, Smith J, Schaeffler BA, et al
    Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
    Neurology. 2020 Mar 24. pii: WNL.0000000000009169.
    PubMed     Abstract available


    February 2020
  41. COSTELLO FE, Bisdorff AR, Robbins MS
    Visual snow: Are we beginning to see the light?
    Neurology. 2020;94:241-242.
    PubMed    


  42. PULEDDA F, Schankin C, Goadsby PJ
    Visual snow syndrome: A clinical and phenotypical description of 1,100 cases.
    Neurology. 2020;94:e564-e574.
    PubMed     Abstract available


  43. LEIRA R, Dominguez C
    Author response: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2020;94:235-236.
    PubMed    


  44. WELCH KMA
    Reader response: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2020;94:235.
    PubMed    


  45. GUPTA V
    Reader response: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2020;94:234.
    PubMed    


  46. SHUBHAKARAN K
    Reader response: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2020;94:233-234.
    PubMed    


  47. LEWIS A, Galetta S
    Editors' note: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2020;94:233.
    PubMed    


    January 2020
  48. ROCCA MA, Harrer JU, Filippi M
    Are machine learning approaches the future to study migraine patients?
    Neurology. 2020 Jan 21. pii: WNL.0000000000008956.
    PubMed    


  49. TU Y, Zeng F, Lan L, Li Z, et al
    An fMRI-based neural marker for migraine without aura.
    Neurology. 2020 Jan 21. pii: WNL.0000000000008962.
    PubMed     Abstract available


  50. MULLIN K, Kudrow D, Croop R, Lovegren M, et al
    Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
    Neurology. 2020 Jan 13. pii: WNL.0000000000008944.
    PubMed     Abstract available


    December 2019
  51. KUDROW D, Pascual J, Winner PK, Dodick DW, et al
    Vascular safety of erenumab for migraine prevention.
    Neurology. 2019 Dec 18. pii: WNL.0000000000008743.
    PubMed     Abstract available


  52. BERTISCH SM, Li W, Buettner C, Mostofsky E, et al
    Nightly sleep duration, fragmentation, and quality and daily risk of migraine.
    Neurology. 2019 Dec 16. pii: WNL.0000000000008740.
    PubMed     Abstract available



  53. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
    Neurology. 2019 Dec 10. pii: WNL.0000000000008728.
    PubMed    



  54. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
    Neurology. 2019 Dec 10. pii: WNL.0000000000008750.
    PubMed    


    November 2019
  55. TAN RYY, Traylor M, Megy K, Duarte D, et al
    How common are single gene mutations as a cause for lacunar stroke? A targeted gene panel study.
    Neurology. 2019 Nov 12. pii: WNL.0000000000008544.
    PubMed     Abstract available


  56. LIPTON RB, Fanning KM, Buse DC, Martin VT, et al
    Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.
    Neurology. 2019 Nov 5. pii: WNL.0000000000008589.
    PubMed     Abstract available


    October 2019
  57. LAHUE SC, Gelfand AA, Bove RM
    Navigating monoclonal antibody use in breastfeeding women: Do no harm or do little good?
    Neurology. 2019;93:668-672.
    PubMed     Abstract available


  58. SEN S
    Author response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.
    Neurology. 2019;93:646-647.
    PubMed    


  59. HSIEH CY
    Reader response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.
    Neurology. 2019;93:646.
    PubMed    


  60. GUPTA V
    Reader response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.
    Neurology. 2019;93:645-646.
    PubMed    


  61. LEWIS A, Galetta S
    Editors' note: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.
    Neurology. 2019;93:645.
    PubMed    


    September 2019
  62. BEH SC, Friedman DI
    Acute vestibular migraine treatment with noninvasive vagus nerve stimulation.
    Neurology. 2019 Sep 25. pii: WNL.0000000000008388.
    PubMed     Abstract available



  63. Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine.
    Neurology. 2019;93:608.
    PubMed    


    July 2019
  64. ROBBINS MS
    Comment: Time for neurologists to see visual snow.
    Neurology. 2019;93:153.
    PubMed    


    June 2019
  65. YOUNG AS, Lechner C, Bradshaw AP, MacDougall HG, et al
    Capturing acute vertigo: A vestibular event monitor.
    Neurology. 2019;92:e2743-e2753.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: